Your browser doesn't support javascript.
loading
Minimum data set for treatment effectiveness in pyoderma gangrenosum (MIDSTEP): an international protocol of an e-Delphi study to develop a clinical physician-driven treatment effectiveness registry on behalf of the UPGRADE initiative.
Haddadin, Olivia M; Jacobson, Michael E; Chen, Diana M; Croitoru, David O; Dissemond, Joachim; Gontijo, Joao Renato V; Hampton, Philip J; Kelly, Robert I; Marzano, Angelo Valerio; Tada, Yayoi; Gerbens, Louise A A; Ortega-Loayza, Alex G.
Afiliação
  • Haddadin OM; School of Medicine, Oregon Health and Science University, Portland, OR, USA.
  • Jacobson ME; Department of Dermatology, Center for Health and Healing, Oregon Health and Science University, Portland, OR, USA.
  • Chen DM; Genentech, Inc, South San Francisco, CA, USA.
  • Croitoru DO; Division of Dermatology, Department of Medicine, Women's College Hospital, University of Toronto, Toronto, Canada.
  • Dissemond J; Department of Dermatology, Venerology and Allergology, University of Essen, Essen, Germany.
  • Gontijo JRV; Professor of Dermatology, Medical School of Universidade Federal de Minas Gerais, Belo Horizonte, MG, Brazil.
  • Hampton PJ; Department of Dermatology, The Royal Victoria Infirmary, Newcastle upon Tyne, UK.
  • Kelly RI; Department of Dermatology, St Vincent's Hospital, Melbourne, Australia.
  • Marzano AV; Dermatology Unit, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy.
  • Tada Y; Department of Dermatology, Teikyo University School of Medicine, Tokyo, Japan.
  • Gerbens LAA; Department of Dermatology, Academic Medical Center, University of Amsterdam, Meibergdreef 9, 1105, Amsterdam, The Netherlands.
  • Ortega-Loayza AG; Department of Dermatology, Center for Health and Healing, Oregon Health and Science University, Portland, OR, USA. ortegalo@ohsu.edu.
Arch Dermatol Res ; 315(10): 2913-2919, 2023 Dec.
Article em En | MEDLINE | ID: mdl-37755505
ABSTRACT
Pyoderma gangrenosum (PG) is a rare inflammatory condition with an immense disease burden that remains understudied. With limited approved treatments and low-quality clinical evidence, PG continues to have poor patient outcomes. Unfortunately, improvement in PG treatments and patient care is based on additional research endeavors that can only be developed from existing high-quality data. The following protocol outlines the development of the Minimum Data Set for Treatment Effectiveness in Pyoderma gangrenosum (MIDSTEP), a core set of domains and domain items for the Pyoderma Gangrenosum Treatment Effectiveness (PyGaTE) international registry. The outcomes and benefits are focused on providing real-world data for physicians to improve their clinical decisions on PG treatment and inform clinical trial design, promoting clinical research among the international scientific community. MIDSTEP is a multi-phase project. The first phase will produce a domain item list from a literature review to take into the second phase which would finalize the core data set by an e-Delphi exercise. There will be a single stakeholder group participating together in the e-Delphi consisting of PG experts (healthcare providers, researchers, methodologists, industry representatives, and regulators), ulcerative PG patients, and PG patient advocates. The methodology outlined in the protocol is a systematic method based on several guidelines through COMET and established dermatologic registries and outcome sets with systematic methodologies of their own. The third phase will identify the instruments for the items, the 'when to measure' the items, and the platform for the registry. The last phase is the implementation and continued maintenance of the international registry PyGaTE. By solidifying a consensus on standardized outcomes and collecting information on PG treatment effectiveness in a centralized database, existing treatments can be compared more systematically and analyzed with increased evidence. MIDSTEP and the PyGaTE international registry will have the ambitious goal to generate and disseminate real-world data that can be used by all stakeholders to improve health outcomes for PG patients. Future potential for the outcome of this project includes the development of a gold-standard PG treatment.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Médicos / Pioderma Gangrenoso Tipo de estudo: Guideline / Prognostic_studies Limite: Humans Idioma: En Ano de publicação: 2023 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Médicos / Pioderma Gangrenoso Tipo de estudo: Guideline / Prognostic_studies Limite: Humans Idioma: En Ano de publicação: 2023 Tipo de documento: Article